Intra Nasal Use of Ethylene Diamine Tetra Acetic Acid for Improving Olfactory Dysfunction Post COVID-19
BACKGROUND: COVID-19 has been associated with olfactory dysfunction in many infected patients. The rise of calcium levels in the nasal secretions plays an essential role in the olfaction process with a desensitization effect on the olfactory receptor neurons and a negative impact on the olfaction transmission. Ethylene diamine tetra acetic acid (EDTA) is a chelating agent that can bind free calcium in the nasal secretions, thereby reducing the adverse effects of calcium on olfactory function.
OBJECTIVES: The objective of this work is to demonstrate the effect of intranasal EDTA on improving olfactory dysfunction following COVID-19.
METHODS: Fifty patients with a history of COVID-19 and olfactory dysfunction that persisted for more than 6 months were enrolled in the current prospective randomized clinical trial. Participants were randomized into 2 equal groups. Twenty-five patients were treated with olfactory training only, while the remaining 25 patients received treatment with olfactory training and a topical nasal spray of ethylene diamine tetra acetic acid. The olfactory function was assessed before treatment and 3 months later using the Sniffin' Sticks test. Additionally, the determination of calcium level in the nasal secretions was performed using an ion-selective electrode before treatment and 3 months later.
RESULTS: Eighty-eight percent of the patients treated with olfactory training in addition to EDTA exhibited clinical improvement, while 60% showed improvement in patients treated with olfactory training only. Furthermore, a significant decrease in the measured calcium level in the nasal secretions was demonstrated after the use of ethylene diamine tetra compared to patients treated with olfactory training only.
CONCLUSION: Ethylene diamine tetra acetic acid may be associated with an improvement of the olfactory function post-COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
American journal of rhinology & allergy - 37(2023), 6 vom: 03. Nov., Seite 630-637 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abdelazim, Mohamed H [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.10.2023 Date Revised 05.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/19458924231184055 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36280172X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36280172X | ||
| 003 | DE-627 | ||
| 005 | 20231226092011.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/19458924231184055 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM36280172X | ||
| 035 | |a (NLM)37786364 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abdelazim, Mohamed H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intra Nasal Use of Ethylene Diamine Tetra Acetic Acid for Improving Olfactory Dysfunction Post COVID-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.10.2023 | ||
| 500 | |a Date Revised 05.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: COVID-19 has been associated with olfactory dysfunction in many infected patients. The rise of calcium levels in the nasal secretions plays an essential role in the olfaction process with a desensitization effect on the olfactory receptor neurons and a negative impact on the olfaction transmission. Ethylene diamine tetra acetic acid (EDTA) is a chelating agent that can bind free calcium in the nasal secretions, thereby reducing the adverse effects of calcium on olfactory function | ||
| 520 | |a OBJECTIVES: The objective of this work is to demonstrate the effect of intranasal EDTA on improving olfactory dysfunction following COVID-19 | ||
| 520 | |a METHODS: Fifty patients with a history of COVID-19 and olfactory dysfunction that persisted for more than 6 months were enrolled in the current prospective randomized clinical trial. Participants were randomized into 2 equal groups. Twenty-five patients were treated with olfactory training only, while the remaining 25 patients received treatment with olfactory training and a topical nasal spray of ethylene diamine tetra acetic acid. The olfactory function was assessed before treatment and 3 months later using the Sniffin' Sticks test. Additionally, the determination of calcium level in the nasal secretions was performed using an ion-selective electrode before treatment and 3 months later | ||
| 520 | |a RESULTS: Eighty-eight percent of the patients treated with olfactory training in addition to EDTA exhibited clinical improvement, while 60% showed improvement in patients treated with olfactory training only. Furthermore, a significant decrease in the measured calcium level in the nasal secretions was demonstrated after the use of ethylene diamine tetra compared to patients treated with olfactory training only | ||
| 520 | |a CONCLUSION: Ethylene diamine tetra acetic acid may be associated with an improvement of the olfactory function post-COVID-19 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a EDTA | |
| 650 | 4 | |a Sniffin’ sticks | |
| 650 | 4 | |a anosmia | |
| 650 | 4 | |a calcium | |
| 650 | 4 | |a chelating agent | |
| 650 | 4 | |a hyposmia | |
| 650 | 4 | |a olfactory dysfunction | |
| 650 | 4 | |a randomized | |
| 650 | 4 | |a sodium chloride | |
| 650 | 7 | |a Acetic Acid |2 NLM | |
| 650 | 7 | |a Q40Q9N063P |2 NLM | |
| 650 | 7 | |a Calcium |2 NLM | |
| 650 | 7 | |a SY7Q814VUP |2 NLM | |
| 650 | 7 | |a Edetic Acid |2 NLM | |
| 650 | 7 | |a 9G34HU7RV0 |2 NLM | |
| 650 | 7 | |a Ethylenes |2 NLM | |
| 700 | 1 | |a Mandour, Zeyad |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelazim, Ahmed H |e verfasserin |4 aut | |
| 700 | 1 | |a Ismaiel, Wael F |e verfasserin |4 aut | |
| 700 | 1 | |a Gamal, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Abourehab, Mohammed A S |e verfasserin |4 aut | |
| 700 | 1 | |a Alghamdi, Saleh |e verfasserin |4 aut | |
| 700 | 1 | |a Alghamdi, Mohamed A |e verfasserin |4 aut | |
| 700 | 1 | |a Alrugi, Rehab R |e verfasserin |4 aut | |
| 700 | 1 | |a Alharthi, Rawan R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of rhinology & allergy |d 2009 |g 37(2023), 6 vom: 03. Nov., Seite 630-637 |w (DE-627)NLM187939225 |x 1945-8932 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:6 |g day:03 |g month:11 |g pages:630-637 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/19458924231184055 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 6 |b 03 |c 11 |h 630-637 | ||